M1 Kliniken

Adjusted figures show M1 Kliniken’s core business increased revenue in H1 2026 by 11% to €56.9m and improved EBIT by almost 24% to €18.6m; in Q2 revenue growth accelerated to around 16%. The prior sharp decline in group metrics resulted from the deconsolidation and sale of wholesale subsidiary Haemato Pharm. Management confirms a mid-term target of €200–300m revenue by 2029 with an EBIT margin of at least 20% (H1 margin: >32%). Analysts raised the price target, leaving upside of almost 50%; the P/E for 2026 is expected to be below 14. » Más en finanzen.net

M1 Kliniken's stock has risen in recent months to close to its all-time high. The Düsseldorf-based company reports robust growth and surprised with a significantly increased dividend. If the ambitious forecasts are met, the authors see further upside potential for the share price. » Más en finanzen.net

M1 Kliniken reports for 2025 a revenue increase of 7.4% to €364.3m and EBIT growth of 29.2% to €34.6m; the beauty clinics recorded revenue growth of 11.2% and an EBIT gain of 41.5%. The dividend is to rise from €0.50 to €1.20 per share, equivalent to a yield of more than 6%. Management reaffirms the mid‑term guidance of €200–300m in revenue and a sustainable EBIT margin of 20% by 2029; acquisitions are not excluded as a growth driver. A reduced share count due to buybacks and a cash reserve of more than €30m support further upside potential for the stock. » Más en finanzen.net